GKOS News and Press, Glaukos Corporation From 03/02/24

2024-03-02 07:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-02-21 16:42:49 ET More on Glaukos Glaukos: Remains A Hold Due To High Valuation And Negative Profitability Glaukos Q4 2023 Earnings Preview Sight Sciences slips despite Medicare decision on glaucoma procedure (update) Seeking Alpha’s Quant Rating ...

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the fourth quarter and full year ended December 31, 2023. Key highl...

Vimeo Inc. (VMEO) is expected to report $-0.01 for Q4 2023 Heineken N.V ADR (HEINY) is expected to report for Q4 2023 American States Water Company (AWR) is expected to report $0.53 for Q4 2023 NextPlay Technologies Inc. (NXTP) is expected to report for Q3 2024 Inseego Corp. (INSG...

2024-02-20 17:20:57 ET More on Glaukos Glaukos: Remains A Hold Due To High Valuation And Negative Profitability Sight Sciences slips despite Medicare decision on glaucoma procedure (update) Sight Sciences climbs after update on Medicare coverage for glaucoma procedur...

2024-02-16 07:30:02 ET Truist Financial analyst issues BUY recommendation for GKOS on February 16, 2024 07:00AM ET. The previous analyst recommendation was Buy. GKOS was trading at $96.11 at issue of the analyst recommendation. The overall analyst consensus : BUY. Cu...

2024-02-09 20:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Conference Call and Webcast Scheduled for 1:30 p.m. PT Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release fourth quarter and full...

2024-01-09 09:50:03 ET More on Glaukos Glaukos: Remains A Hold Due To High Valuation And Negative Profitability Glaukos Q3 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Glaukos For further details see: Glaukos says 2023 revenue to b...

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced its preliminary, unaudited net sales for the fourth quarter and full year ended December ...